X0206 3 2015-06-16 0 0001626199 Nivalis Therapeutics, Inc. NVLS 0001645257 Hawkes Bay Master Investors (Cayman) L.P. C/O WELLINGTON MANAGEMENT COMPANY LLP 280 CONGRESS STREET BOSTON MA 02210 0 0 1 0 Series 2 convertible preferred stock Common stock 283390 D Each share of Series 2 convertible preferred stock is convertible into shares of common stock on a 2.889-for-1 basis at the option of the reporting person or upon the occurrence of certain events. All outstanding shares of Series 2 convertible preferred stock are expected to convert into shares of common stock immediately prior to the amendment and restatement by Nivalis Therapeutics, Inc. of its certificate of incorporation, provided the amendment and restatement occurs prior to, and on the same day as, the closing of its initial public offering at an initial public offering price of no less than $8.667 per share. Hawkes Bay Master Investors (Cayman) LP By: Wellington Hedge Management LLC, as General Partner, /s/Valerie Tipping, Title: Authorized Person 2015-06-16